HC Wainwright Reaffirms “Buy” Rating for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They currently have a $7.00 price objective on the stock.

KPTI has been the topic of a number of other reports. Piper Sandler boosted their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. Royal Bank of Canada reissued an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a report on Monday, February 10th. Finally, StockNews.com lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 22nd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Karyopharm Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Price Performance

Shares of NASDAQ:KPTI opened at $0.60 on Thursday. The firm has a market capitalization of $75.71 million, a price-to-earnings ratio of -0.53 and a beta of 0.06. Karyopharm Therapeutics has a 12 month low of $0.53 and a 12 month high of $1.70. The business’s 50 day simple moving average is $0.67 and its 200-day simple moving average is $0.76.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings data on Wednesday, February 19th. The company reported ($0.24) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.02. On average, equities analysts anticipate that Karyopharm Therapeutics will post -0.83 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Velan Capital Investment Management LP bought a new position in shares of Karyopharm Therapeutics in the fourth quarter valued at about $27,000. Focus Partners Wealth acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $31,000. TD Waterhouse Canada Inc. bought a new position in shares of Karyopharm Therapeutics during the fourth quarter worth $32,000. Two Sigma Advisers LP lifted its holdings in Karyopharm Therapeutics by 145.5% during the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after acquiring an additional 45,400 shares in the last quarter. Finally, Opti Capital Management LP acquired a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $85,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).